← All indications
Premenstrual Syndrome
A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
Subtype terms (1)
More specific conditions that are subtypes of Premenstrual Syndrome in the MeSH hierarchy.
- Premenstrual Dysphoric Disorder
16 drugs (10 approved, 6 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (10)
Phase 3 trials (6)
Phase 2 trials (2)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (17)
- Forest Laboratories
- Novo Nordisk
- Clinvest
- Endo Pharmaceuticals
- GlaxoSmithKline
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- University of Pennsylvania
- Chulalongkorn University
- Cornell University
- Harvard University
- Yale University
- Karolinska Institute
- University of Gothenburg
- Scott and White Healthcare
- JayMac Pharmaceuticals, LLC
- Allergan PLC (2015)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (2)
Organization Involved with Other Experimental Indications (5)